Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748488 | 0.77 | AR (0.50) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL26986702 | 0.76 | AR (0.51) | ARMAPTTAS2R14 | |
| SCHEMBL3289361 | 0.76 | AR (0.52) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL3416477 | 0.76 | AR (0.49) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL3291274 | 0.75 | AR (0.57) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL4894829 | 0.75 | AR (0.56) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL3289311 | 0.74 | AR (0.52) | ARPGRTAS2R14 | |
| SCHEMBL26364991 | 0.74 | AR (0.51) | ARCYP2C19MAPTTAS2R14 | |
| SCHEMBL30104704 | 0.74 | AR (0.51) | ARCYP2C19MAPTTAS2R14 | |
| SCHEMBL20459116 | 0.74 | AR (0.60) | ARPGRCYP2C19ABCB11ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | AR, NR3C2, NR5A1 | AR 1/4885PGR 24/4885CYP2C19 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.